This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lutsar, I.
Right arrow Articles by McCracken, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lutsar, I.
Right arrow Articles by McCracken, G. H., Jr.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1805-1807, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Efficacy of Gatifloxacin in Experimental Escherichia coli Meningitis

Irja Lutsar,* Ian R. Friedland, Hasan S. Jafri, Loretta Wubbel, Winston Ng, Faryal Ghaffar, and George H. McCracken Jr.

The University of Texas Southwestern Medical Center, Dallas, Texas

Received 10 June 1998/Returned for modification 15 November 1998/Accepted 5 May 1999

The effectiveness of gatifloxacin therapy (15 mg/kg every 5 h [q5h]) was compared with that of meropenem (75 mg/kg q5h) and cefotaxime (75 mg/kg q5h) therapy in experimental meningitis caused by a beta -lactamase-producing strain of Escherichia coli. Gatifloxacin therapy was more rapidly bactericidal than cefotaxime but similar to meropenem therapy (bacterial killing rates at 5 h, 0.83 ± 0.26, 0.46 ± 0.3, and 0.73 ± 0.17 CFU/ml/h, respectively; P = 0.03 for gatifloxacin versus cefotaxime). At 10 h, seven of eight animals treated with gatifloxacin had <10 CFU/ml in their cerebrospinal fluid, compared with one of seven treated with cefotaxime therapy (P = 0.01). Gatifloxacin was at least as effective as currently available antibiotics in this model of E. coli meningitis.


* Corresponding author. Mailing address: Department of Pediatrics, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9063. Phone: (214) 648-3082. Fax: (214) 648-2961. E-mail: ilutsa{at}mednet.swmed.edu.


Antimicrobial Agents and Chemotherapy, July 1999, p. 1805-1807, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Rodriguez-Cerrato, V., McCoig, C. C., Michelow, I. C., Ghaffar, F., Jafri, H. S., Hardy, R. D., Patel, C., Olsen, K., McCracken, G. H. Jr. (2001). Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis. Antimicrob. Agents Chemother. 45: 3092-3097 [Abstract] [Full Text]